Literature DB >> 11307775

Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.

M C Kyrtsonis, S I Kokoris, F N Kontopidou, M P Siakantaris, C Kittas, G A Pangalis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11307775     DOI： 10.1182/blood.v97.8.2527

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

Review 1.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis.

Authors:  Pasquale Niscola; Gianfranco Catalano; Stefano Fratoni; Laura Scaramucci; Paolo de Fabritiis; Tommaso Caravita
Journal:  Blood Res       Date:  2013-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.